3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Completed
2
Enrolling by invitation
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Conditions
Breast Neoplasms
682
Neoplasms
594
Carcinoma, Non-Small-Cell Lung
293
Colorectal Neoplasms
292
Prostatic Neoplasms
284
Lung Neoplasms
224
Melanoma
161
Multiple Myeloma
151
Neoplasm Metastasis
146
Pancreatic Neoplasms
143
Head and Neck Neoplasms
143
Ovarian Neoplasms
136
Carcinoma, Hepatocellular
126
Leukemia, Myeloid, Acute
123
Colonic Neoplasms
114
Brain Neoplasms
113
Squamous Cell Carcinoma of Head and Neck
111
Uterine Cervical Neoplasms
109
Stomach Neoplasms
106
Recurrence
101
Lymphoma
101
Glioblastoma
96
Precursor Cell Lymphoblastic Leukemia-Lymphoma
83
Lymphoma, Non-Hodgkin
82
Hematologic Neoplasms
80
Urinary Bladder Neoplasms
78
Lymphoma, Follicular
78
Glioma
77
Parkinson Disease 4, Autosomal Dominant Lewy Body
74
Sarcoma
72
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Amyloid Neuropathies, Familial
×
1 year
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled
NCT03431896
2026-03-12
MED-hATTR
The Cleveland Clinic
Completed
37 enrolled